

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

September 15th, 2023

Selected for the latest edition of the Weekly Toyo Keizai "100 Amazing Venture Businesses" in 2023

Kanagawa, Japan, September 15th, 2023 – Chordia Therapeutics Inc. (“Chordia”), announced that our company has been selected for the latest edition of the "Amazing Venture 100" published by the business economic magazine Weekly Toyo Keizai in 2023. Chordia is honored to be selected in the field of "Medical and Drug Discovery" for its development of first-in-class small molecule anti-cancer drugs and for its outstanding track record and network in the field of academic collaboration.

About the Weekly Toyo Keizai "Amazing Venture 100"

The "Amazing Venture 100" selects 100 new venture companies each year that are candidates for future unicorns based on criteria such as the size of their fundraising and the uniqueness of their business and technology.

Complete list of the latest edition of the "100 Amazing Ventures" 2023

Here are the unicorns of the future who will innovate:

<https://toyokeizai.net/articles/-/695368>

About Chordia Therapeutics

Chordia was established in November 2017 at Shonan Health Innovation Park (“Shonan iPark”) in Fujisawa, Kanagawa Prefecture, as a biotech company engaged in the research and development of novel therapies for cancers, with the goal of researching and developing first-in-class anti-cancer drugs and creating innovative new drugs.

In addition to its leading program for CTX-712, Chordia is engaged in the research of several developments in our pipeline, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Established: November 2017
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,
Kanagawa 251-0012, Japan
Representative: Hiroshi Miyake, Representative Director
Website: <https://www.chorditherapeutics.com/en/>

For more information, contact, IR Mizobe: ir@chorditherapeutics.com